Literature DB >> 23239911

Multidisciplinary approach for patients with esophageal cancer.

Victoria M Villaflor1, Marco E Allaix, Bruce Minsky, Fernando A Herbella, Marco G Patti.   

Abstract

Patients with esophageal cancer have a poor prognosis because they often have no symptoms until their disease is advanced. There are no screening recommendations for patients unless they have Barrett's esophagitis or a significant family history of this disease. Often, esophageal cancer is not diagnosed until patients present with dysphagia, odynophagia, anemia or weight loss. When symptoms occur, the stage is often stage III or greater. Treatment of patients with very early stage disease is fairly straight forward using only local treatment with surgical resection or endoscopic mucosal resection. The treatment of patients who have locally advanced esophageal cancer is more complex and controversial. Despite multiple trials, treatment recommendations are still unclear due to conflicting data. Sadly, much of our data is difficult to interpret due to many of the trials done have included very heterogeneous groups of patients both histologically as well as anatomically. Additionally, studies have been underpowered or stopped early due to poor accrual. In the United States, concurrent chemoradiotherapy prior to surgical resection has been accepted by many as standard of care in the locally advanced patient. Patients who have metastatic disease are treated palliatively. The aim of this article is to describe the multidisciplinary approach used by an established team at a single high volume center for esophageal cancer, and to review the literature which guides our treatment recommendations.

Entities:  

Keywords:  Chemoradiotherapy; Esophageal Cancer; Esophageal resection; Esophagectomy; Multidisciplinary therapy; Multimodality therapy

Mesh:

Year:  2012        PMID: 23239911      PMCID: PMC3520162          DOI: 10.3748/wjg.v18.i46.6737

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  87 in total

Review 1.  High volume centers for esophagectomy: what is the number needed to achieve low postoperative mortality?

Authors:  R Metzger; E Bollschweiler; D Vallböhmer; M Maish; T R DeMeester; A H Hölscher
Journal:  Dis Esophagus       Date:  2004       Impact factor: 3.429

Review 2.  Targeted therapies for esophageal cancer.

Authors:  William P Tew; David P Kelsen; David H Ilson
Journal:  Oncologist       Date:  2005-09

3.  Outcome of surgical treatment for early adenocarcinoma of the esophagus or gastro-esophageal junction.

Authors:  Marinke Westerterp; Linetta B Koppert; Christianne J Buskens; Hugo W Tilanus; Fiebo J W ten Kate; Jacques J H G M Bergman; Peter D Siersema; Herman van Dekken; Jan J B van Lanschot
Journal:  Virchows Arch       Date:  2005-04-19       Impact factor: 4.064

4.  Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus.

Authors:  Michael Stahl; Martin Stuschke; Nils Lehmann; Hans-Joachim Meyer; Martin K Walz; Siegfried Seeber; Bodo Klump; Wilfried Budach; Reinhard Teichmann; Marcus Schmitt; Gerd Schmitt; Claus Franke; Hansjochen Wilke
Journal:  J Clin Oncol       Date:  2005-04-01       Impact factor: 44.544

5.  Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial.

Authors:  Bryan H Burmeister; B Mark Smithers; Val Gebski; Lara Fitzgerald; R John Simes; Peter Devitt; Stephen Ackland; David C Gotley; David Joseph; Jeremy Millar; John North; Euan T Walpole; James W Denham
Journal:  Lancet Oncol       Date:  2005-09       Impact factor: 41.316

6.  Long-term results of definitive radiotherapy for stage I esophageal cancer.

Authors:  Heitetsu Sai; Michihide Mitsumori; Norio Araki; Takashi Mizowaki; Yasushi Nagata; Yasumasa Nishimura; Masahiro Hiraoka
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-08-01       Impact factor: 7.038

7.  Clinical outcomes of extended esophagectomy with three-field lymph node dissection for esophageal squamous cell carcinoma.

Authors:  Mitsuo Tachibana; Shoichi Kinugasa; Hiroshi Yoshimura; Muneaki Shibakita; Yasuhito Tonomoto; Dipok Kumar Dhar; Naofumi Nagasue
Journal:  Am J Surg       Date:  2005-01       Impact factor: 2.565

Review 8.  Novel targeted therapies in the treatment of gastric and esophageal cancer.

Authors:  J Tabernero; T Macarulla; F J Ramos; J Baselga
Journal:  Ann Oncol       Date:  2005-06-24       Impact factor: 32.976

Review 9.  Preoperative radiotherapy for esophageal carcinoma.

Authors:  S J Arnott; W Duncan; M Gignoux; H S Hansen; B Launois; K Nygaard; M K B Parmar; A Rousell; G Spilopoulos; G Stewart; J F Tierney; M Wang; Z Rhugang
Journal:  Cochrane Database Syst Rev       Date:  2005-10-19

10.  Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction.

Authors:  Michael Stahl; Martin K Walz; Martin Stuschke; Nils Lehmann; Hans-Joachim Meyer; Jorge Riera-Knorrenschild; Peter Langer; Rita Engenhart-Cabillic; Michael Bitzer; Alfred Königsrainer; Wilfried Budach; Hansjochen Wilke
Journal:  J Clin Oncol       Date:  2009-01-12       Impact factor: 44.544

View more
  8 in total

1.  Clinical significance of the expression of EGFR signaling pathway-related proteins in esophageal squamous cell carcinoma.

Authors:  Jian-Cheng Li; Yun-Hui Zhao; Xiao-Ying Wang; Yan Yang; Ding-Long Pan; Zi-Dan Qiu; Ying Su; Jian-Ji Pan
Journal:  Tumour Biol       Date:  2013-09-20

2.  Extended lymphadenectomy in esophageal cancer is debatable.

Authors:  Fernando A M Herbella; Rafael M Laurino Neto; Marco E Allaix; Marco G Patti
Journal:  World J Surg       Date:  2013-08       Impact factor: 3.352

3.  Concurrent Neoadjuvant Chemoradiotherapy for Siewert II and III Adenocarcinoma at Gastroesophageal Junction.

Authors:  Qun Zhao; Yong Li; Jun Wang; Jun Zhang; Xueying Qiao; Bibo Tan; Yuan Tian; Gaofeng Shi; Qian Xu; Ruxun Li; Yueping Liu; Peigang Yang
Journal:  Am J Med Sci       Date:  2015-06       Impact factor: 2.378

4.  Integrin expression in esophageal squamous cell carcinoma: loss of the physiological integrin expression pattern correlates with disease progression.

Authors:  Christian Vay; Stefan B Hosch; Nikolas H Stoecklein; Christoph A Klein; Daniel Vallböhmer; Björn-Christian Link; Emre F Yekebas; Jakob R Izbicki; Wolfram T Knoefel; Peter Scheunemann
Journal:  PLoS One       Date:  2014-11-14       Impact factor: 3.240

5.  Recombinant human endostatin plus paclitaxel/nedaplatin for recurrent or metastatic advanced esophageal squamous cell carcinoma: a prospective, single-arm, open-label, phase II study.

Authors:  Zhi-Qiang Wang; De-Shen Wang; Feng-Hua Wang; Chao Ren; Qiong Tan; Yu-Hong Li
Journal:  Invest New Drugs       Date:  2020-10-18       Impact factor: 3.850

6.  Standardized clinical pathways for esophagectomy are not a reality in Brazil, even with a high prevalence of esophageal cancer and achalasia.

Authors:  Marina Zamuner; Fernando A M Herbella; José L B Aquino
Journal:  Arq Bras Cir Dig       Date:  2015 Jul-Sep

7.  DCE-MRI-Derived Volume Transfer Constant (Ktrans) and DWI Apparent Diffusion Coefficient as Predictive Markers of Short- and Long-Term Efficacy of Chemoradiotherapy in Patients With Esophageal Cancer.

Authors:  Zhi-Min Ye; Shu-Jun Dai; Feng-Qin Yan; Lei Wang; Jun Fang; Zhen-Fu Fu; Yue-Zhen Wang
Journal:  Technol Cancer Res Treat       Date:  2018-01-01

8.  Long-term effects of radiation prior to surgery and chemotherapy on survival of esophageal cancer undergoing surgery.

Authors:  Nan Zhang; Shao-Wei Zhang
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.